Jpmorgan Chase & CO Orgenesis Inc. Transaction History

Jpmorgan Chase & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$0.39 - $0.63 $1 - $2	4 Added 2.58%	159 $0
Q1 2024 May 10, 2024	BUY	$0.28 - $0.9 $3 - $12	14 Added 9.93%	155 $0
Q4 2023 Feb 12, 2024	BUY	$0.44 - $0.96 $5 - $11	12 Added 9.3%	141 $0
Q3 2023 Nov 14, 2023	BUY	$0.41 - $1.4 $13 - $47	34 Added 35.79%	129 $0
Q2 2023 Aug 11, 2023	SELL	$1.01 - $1.44 $2,056 - $2,931	-2,036 Reduced 95.54%	95 $0
Q1 2023 May 11, 2023	BUY	$1.18 - $2.59 $2,402 - $5,273	2,036 Added 2143.16%	2,131 $2,000
Q4 2022 Feb 13, 2023	SELL	$1.18 - $2.24 $4 - $8	-4 Reduced 4.04%	95 $0
Q3 2022 Nov 14, 2022	BUY	$1.38 - $2.38 $5 - $9	4 Added 4.21%	99 $0
Q3 2021 Nov 12, 2021	BUY	$4.6 - $5.44 $436 - $516	95 New	95 $0

134K

Ticker ORGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,545,800
Market Cap $28.1M
Description
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.